Pre-clinical study.
Agree it is undervalued, however AGN is several years ahead on the clinical timeline - having completed a phase 1 and started dosing in a placebo-controlled double-blind phase 2. Plus ODD designation for HIE. I'd argue that AGN is also undervalued.
Ann: Nyrada Commences Walter Reed Traumatic Brain Injury Study, page-3
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.82M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 35.0¢ | 31.0¢ | $188.4K | 569.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7500 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 30034 | 2 |
View Market Depth
| Last trade - 15.33pm 22/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |